Biotechnological human antibody drug agent for use in the treatment of cancer and eye diseases
- Recombinant human antibody structures that allow the human-compatible use of two anti-angiogenic recombinant antibodies (KDR1.3 and KDR2.6) for stopping tumor angiogenesis (formation of new blood vessels from existing ones)
Capabilities of Genetic Engineering and Biotechnology Institute:
- Recombinant human antibody library for human-compatible antibody development.
- Infrastructure and know-how on the development of recombinant human antibodies in the treatment of various diseases
- The efficacy of human antibody structures has been demonstrated by cell and mice models.
The invention “Recombinant antibody structures that bind to and block the activity of Vascular Endothelial Growth Factor receptor 2/KDR”, which is used as a pattern in forming human antibody structures, has been registered with an international patent.
United States registration No.: 9193792, Registration date: 24/11/2015
China, registration No.: CN 1031190693 B, Registration date: 29/06/2016